Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Document › Details

Medigene AG. (7/15/14). "Press Release: Medigene Secures Funding for Its Cancer Immunotherapy Programmes through Capital Increase [Not for release, publication or distribution in the United States, Canada, Japan or Australia]". Martinsried.

Organisation Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
Products Product T cell therapy
  Product 2 investment banking
Index terms Index term Medigene–SEVERAL: investment, 201406–201407 capital increase €15.9m 3m new shares + 818.7k convertible bonds
  Index term 2 Trianta Immunotherapies–Medigene: investment, 201401 acquisition 100% for 1m shares worth €4m plus €5.875m milestones in shares or cash
Persons Person Llewellyn-Davies, Peter (Apeiron 201807– CEO before CFO+CBO before Accellerate Partners + Medigene + Wilex)
  Person 2 Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München)
     


   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for Medigene (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top